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Background: Central nervous system (CNS) tumors are the most common solid tumors that occur in children, however
there were few big-data follow-up analysis published in China. Overexpression of epidermal growth factor receptor
(EGFR) family members was reported on glioblastoma (GBM) and medulloblastoma (MB) before. However, the correlation
between EGFR family members expression with prognosis of MB, supratentorial primitive neuroectodermal tumor (PNET)
and small cell GBM is unclear in Chinese children.
Methods: A retrospective and survival analysis was performed on children (age≤ 16 years) diagnosed as CNS primary
small cell tumors in the Affiliated Provincial Hospital, Shandong University from 2000 to 2012, including MB (n = 44),
PNET (n = 8) and small cell GBM (n = 19). The expression of EGFR, ERBB-2, ERBB-3 and ERBB-4 were detected by
immunohistochemistry (IHC). The fluorescence in situ hybridization (FISH) was used to observe the amplification of EGFR
and ERBB-2 gene.
Results: Median survival times of MBs, small GBMs and PNETs were 23 ± 6.7 months, 8 ± 4.7 months and 10 ± 1.4 months.
Expression and amplification of ERBB-2, ERBB-3 and ERBB-4 were not observed in all tumor samples. The multiply Cox
regression suggested the overexpression and amplification of EGFR were negative prognostic factors for MB. Radiotherapy
had the positive function for all pediatric patients.
Conclusion: Overexpression of EGFR predicts poor outcomes of MBs, small cell GBMs and PNETs, suggesting those three
CNS tumor subtypes can be considered as one group for the potential common mechanism. The current individual
treatment and big data analysis of pediatric CNS embryonal tumors and GBM continues to be very challenging in China.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
7649640001237474
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Central nervous system (CNS) tumors are the second
most common group of malignancies among children;
leukemias as a group are the most common. However,
CNS tumors are the most common form of solid tumors
in children. The overall average annual incidence rate
for pediatric CNS tumors (ages 0–19 years) is 5.26 per
100,000 [1]. Embryonal tumors are the most common
CNS neoplasms in infants less than 36 months of age* Correspondence: qi_pang@yahoo.com
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unless otherwise stated.and are described by the World Health Organization
(WHO) classification scheme as undifferentiated small
round cell tumors with divergent patterns of differenti-
ation [2]. Embryonal Tumors include primitive neuroecto-
dermal tumor (PNET), medulloblastoma (MB), atypical
teratoid/rhabdoid tumor, and several other histology types.
Though those tumors in this category are histologically
similar, they have different patterns of incidence and
survival, so it is important to look at them individually.
In USA (United States of America), the incident rate
of CNS embryonal tumors under 14 years old is 0.8 per
100,000 and the median age is 9. In the age 0 ~ 4, the
embryonal tumors are the most common histology, andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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third most common subtype compared with pilocytic as-
trocytoma [1]. Conversely, there were few reports related
with the large-scale follow-up or prognostic analysis of
pediatrics CNS embryonal tumors in china.
MB comprises up to 20% of all pediatric brain tumors
and is currently treated with surgical resection, radiation
therapy, and chemotherapy [3]. Molecular genetic param-
eters, being associated with poorer prognosis of MB,
include overexpressed ERBB-2, high MYCC expression,
and possibly p53 accumulation [4]. The single most-
predictive clinical factor is extent of disease at the time of
diagnosis, patients with disseminated disease fare less well
[5]. Especially ERBB-2, belonging to the human epidermal
growth factor receptor (EGFR) family, is overexpressed in
40% of MBs and its expression correlates with poor
outcome [6]. However, ERBB-2 expression in PNET is
unclear and should be invested. PNET is histologically
similar to classic MB and constitutes 2% of all childhood
brain tumors. The most common sites of PNET onset are
the cerebrum, suprasellar, or pineal region of children in
their first decade of life [6]. Because MB and PNET share
the aggressive biological behavior, it is crucial to determine
the prognostic factors for guiding the individual treatment.
Glioblastoma multiforme (GBM) is the second most
frequently reported malignancy in CNS, which account
for 15.6% of all primary brain tumors in adults. GBMs
are more common in older adults and are uncommon in
children [1]. GBM is frustratingly chemoresistant and fol-
lows a highly aggressive course, with an average survival
of roughly 1 year. Although small cells are common in
GBM, they are predominant or exclusive in a subset
known as small cell GBM [7]. Small cell GBM is a histo-
logical subtype of GBM with characteristic features of
highly proliferative, monotonous small glial cells with high
nuclear cytoplasm ratio. In this study, we also focused on
the prognostic research for small cell astrocytoma/GBM
for the reason that it shares some similar features with
embryonal tumors. The cytogenetical investigations for
IDH1/2 mutation, 1p/19q loss, and PTEN alteration are
strongly supportive methods for the differential diagnosis
of small cell GBM [8]. PTEN also represents a putative
tumor suppressor gene in MB because loss of PTEN func-
tion would contribute to an over-activation of the PI3K/
AKT signaling pathway, which is activated in MB [9].
Mutations in the IDH1/2 genes are similarly detected in
patients with non-glial tumors with the exception of
PNET, which suggesting the unique mechanism of PNET
shared with small cell GBM [10]. Therefore, small cell
GBM shares the similar genetics and histopathology
features with MB and PNET, and we group them together
as pediatrics CNS small cell tumors in this study.
The members of the EGFR family have been linked to
the astrocytic tumors malignant transformation. Thisreceptor family consists of four tyrosine kinase recep-
tors, ERBB1-4, and seems to be involved in tumor cell
proliferation, differentiation and cell survival [11]. Due
to overexpression of the ERBB1-4 proteins on the sur-
face of neoplastic astrocytes, they are candidates for
targeted therapy [12]. Such treatment, however, requires
reliable detection systems for these receptor proteins in
tumor tissue. EGFR gene amplification can now simply be
evaluated by means of fluorescence in situ hybridization
(FISH) [13]. Several studies have shown a varying degree
amplification of the EGFR (ERBB1) gene, located on
chromosome 7, in GBM [14]. EGFR gene amplification
distinguishes small cell GBM from anaplastic oligodendro-
gliomas [7], nevertheless the spectrum of clinicopathologic
and prognostic features has not been explored fully in
small cell GBM. And the other members of EGFR family
expression levels and their correlation with prognosis are
also unclear.
In china, according our investigation, most hospitals even
only offer patient surgical resection without radiation or
chemotherapy. It is important to raise the neurosurgeons
and oncologic doctors attention for combining various
forms treatment to increase young patients disease-free sur-
vival time and improve the quality of life. For pathologists’
responsibility, finding the prognostic factors of pediatrics
CNS small cell tumors becomes the important task to give
the physicians suggestion. This study was also designed
to investigate the clinical features and the extent of
ERBB-1 ~ 4 gene expression in the small cell GBM, PNET
and MB. Further and most importantly, we assumed to
explore the prognosis factors in children small cell CNS
tumors.
Data collection and methods
Clinical data collection
All 71 pediatric (≤16 year-old) CNS primary small cell
tumors out of 383 children CNS primary tumors (18.54%)
were operated at the Department of Neurosurgery, Affili-
ated Provincial Hospital, Shandong University, Jinan,
China, and consecutively collected in the time period
2000 to 2012, including 44 cases medulloblastoma (MB),
8 cases primitive neuroectodermal tumor (PNET) and 19
cases small cell glioblastoma (GBM). A statistical analysis
was performed to collect demographic and clinical data
that included age, sex, tumor localization, treatment mo-
dalities, and postoperative survival (Additional file 1).
Craniotomies were performed under general anesthesia,
and all patients underwent magnetic resonance imaging
(MRI) a few days before and within 72 hours after surgery.
The extent of tumor resection was determined by the
postoperative MRI scans, defined as gross total resection
or partial resection (residual volume exceeding 2 cm). The
data and tumor specimens were retrieved and revised in
2013 by neurosurgeons and pathologists in Provincial
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Tumors of the Central Nervous System [2]. All specimens
were taken during the patients’ first surgery.
Immunohistochemistry (IHC)
Expression of ERBB1-4 receptor proteins was determined
by IHC using commercial monoclonal antibodies EGFR
(1:50, Santa Cruz), ERBB-2 (1:50, Santa Cruz), ERBB-3
(1:50, Santa Cruz) and ERBB-4 (1:50, Santa Cruz). The
proliferation of tumor cells was detected by ki-67 IHC
staining. Formalin-fixed and paraffin-embedded sections,
4 μm thick, with representative tumor tissue, were incu-
bated with primary antibodies after antigen retrieval by
pressure autoclaving. An automatized histostainer was
used for the immunohistochemcial procedures (Dako
Autostainer, Denmark). For visualization of immunoreac-
tivity, DAKO EnVision system was used with diaminoben-
zidin as chromogene. Sections were counterstained with
haematoxylin. Positive controls were included in each
staining run.
The immunoreactivity was assessed by means of inten-
sity and percentage of immunoreactive tumor cells. Inten-
sity was recorded as 0 (no reaction) to 3 (strong reaction).
Fraction of immunoreactive tumor cells was recorded as 0
(no positive cells), 1 (<10% positive cells), 2 (10-50% posi-
tive cells), or 3 (>50% positive cells). A staining index was
calculated as the product of intensity and fraction of posi-
tive tumor cells [15].
FISH (Fluorescence in situ hybridization)
The copy number of EGFR and ERBB-2 can be deter-
mined by direct fluorescence in situ hybridization (FISH)
[16,17].
EGFR/CEN-7 FISH Probe Mix (DakoCytomation) and
the Histology FISH Accessory Kit (Dako) were applied for
gene copy number detection of the EGFR gene located on
chromosome 7p11.2 and for copy number detection of
the chromosome 7 centromere region (chromosome 7
copy number detection). The Red-labeled DNA probe
(EGFR) binds to a 196 kb segment containing the EGFR
gene on chromosome 7q11.2. The fluorescein Green-
labeled probe (CEN-7) binds to the centromeric region of
chromosome 7. The PathVysion ERBB-2/HER-2 probe kit
(Abbott Molecular) was used for the FISH analysis. The
protocol was similar with EGFR gene FISH staining. Slides
were hybridized with prewarmed probes for the ERBB-2
gene (orange) and chromosome 17 centromere (Her2/
neu/CEP17 SG probe, Vysis) overnight at 37°C.
In brief, the sections were de-paraffinised using xylene,
rehydrated, and pretreated using DAKO solution kit (Hist-
ology FISH Accessory kit). The probes were added to the
sections, coverslipped, sealed with rubber cement, and
placed in a DAKO Hybridizer. The sections and probes
were co-denatured for 5 min at 73°C, followed byannealing at 37°C over night. After hybridization slides
were washed in 0.4 × SSC (with detergent) at 73°C for two
minutes followed by one minutes in 2 × SSC at room
temperature. Then the sections underwent dehydrating in
ethanol three times for 3 min. The slides were counter-
stained and embedded with a 4,6-diamidino-2-phenylin-
dole/antifade solution (DAKO). FISH signals for each
locus-specific FISH probe were assessed under a Nikon
Eclipse 90i microscope (Nikon, Tokyo, Japan) equipped
with a triple-pass filter (DAPI/Green/Orange).
The signal enumeration was performed under high
magnification (×1,000). The entire area of tumor tissue
was evaluated in each case, and all nuclei were assessed
for the orange (marker) and green (reference) signals.
For a patient to be included, 100 evaluable cells were to
be assessed. Tumors were interpreted as amplified when
the ratio of HER-2/EGFR signals divided by chromosome
17/7 centromere signals was equal to or greater than 2.2
and the normal specimens showed a ratio of <1.8. Results
at or near the cutoff point (1.8 – 2.2) were repeated with a
fresh specimen slide.
Statistics and follow-up analysis
Statistical analyses were made using SPSS version 16.0
(SPSS Inc., Chicago, IL). Survival time was calculated from
date of surgery to date of death or the termination of
observation. Multiple Cox regression analyze was used to
study the association between sex (categorical variable;
male versus female), age (continuous variable), tumor size
(continuous variable), extent of surgical resection (cat-
egorical variable; gross total resection versus partial resec-
tion), the treatment (categorical variable; no radiotherapy
versus radiotherapy), ki-67 (Staining Index, continuous
variable), ERBB-1 ~ 4 protein expression (Staining Index,
continuous variable) and survival prognosis. The Kaplan-
Meier method was applied to draw the survival curves
and the log-rank test was used for survival analysis. The
association between results from the FISH investigations
(categorical variables; positive versus negative) and sur-
vival were studied in the same manner. The relationship
of IHC and FISH staining between the different tumor
groups was analyzed by non-parametric Kruskal-Wallis H
method. Two-sided P-values less than 0.05 were regarded
as statistically significant.
The study was approved by the Committee for
Medical Research Ethics of Affiliated Provincial Hospital,
Shandong University.
Results
The clinical features and survival times of pediatrics CNS
small cell tumors
From January 2000 to December 2012, 71 cases pediatric
(≤16 year-old) CNS primary small cell tumors were
followed up including MB (44 cases), small cell GBM
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31, 2012, 65 patients were interviewed, of which 40 MB
patients, 17 cases small cell GBM and 8 cases PNET,
accounted for 91.55% of total small cell tumors. 45
patients were dead at the endpoint of observation. The
follow-up time was 4 months to 156 months, with an aver-
age time of 84 months. The median survival time of MB
(23 ± 6.7 months) was much longer than small cell GBM
(8 ± 4.7 months) and PNET patients (10 ± 1.4 months), re-
spectively (Figure 1A).
In 44 cases MB, 27 males and 17 females (M: F =1.59:1)
were involved and the median survival time of female was
24 months while 15 months for men. Of 8 cases PNET, 4
males and 4 females were calculated and the median sur-
vival time of female (10 months) was similar with male
(9 months). Because of the restriction of patient number,
statistics was not applied for PNET. In 19 cases small cell
GBM, 13 males and 6 females were included, and the me-
dian survival time of female was 10 months comparing
with 6 months of male. Although CNS small cell tumors
were more common in male and the median survival time
is longer for female, there was no significant difference
between genders (P > 0.05) (Tables 1, 2, 3).
Compared with small cell GBM and PNET, the age of
onset in MB was younger (year 1.8 ~ 16) and the peak
age was year 8 to 12. The average ages of onset were 11
and 10.5 in the small cell GBM and PNET respectively,
and especially for GBM, the number of patients was
increased with the growth of age (Figure 1B).
The most common site of MB was cerebellar vermis
(30/44) and the average volume was 4.92 cm. The lesion
site of small cell GBM was mainly observed in the cerebralA
Figure 1 The age distribution and keplan-meier survival curves of the p
the pediatrics CNS small cell tumors including 44 cases medulloblastomas (M
in the Affiliated Provincial Hospital, Shandong University from 2000 to 2012. B
pediatric patients. P values: MB: small cell GBM, 0.0005; MB: PNET, 0.0005; sma
log-rank tests.hemispheres (12/19), among which temporal lobe (6/19)
was most usual onset location and the average volume
was 5.13 cm. While half of PNET occurred in the cerebral
hemispheres (4/8), the average volume was 5.25 cm.
Ki-67 staining was applied for the tumor proliferation
determination, and there was no significant difference of
ki-67 expression between 3 different tumor groups (P =
0.305). The positive cases (index 1+, 2+ and 3+) were
accounted for 94.12%, 66.67% and 85.71% of MB, small
cell GBM and PNET respectively (Figure 2 Ki-67 staining).
The median survival time was presented increasing ten-
dency when the percentage of positive ki-67 staining was
lower than 50% in these 3 tumor subtypes, although only
small cell GBM patients showed statistical difference
(Tables 1, 2, 3).
The EGFR gene amplification and protein expression in
pediatric CNS small cell tumors
Tumor tissue samples were available from 34 of the 44 pa-
tients with MB and 15 out of the 19 patients with small
cell GBM. Those tissue samples and all PNET samples
were evaluable by IHC and FISH, although PNET group
did not meet the criteria for statistical analysis because of
too many censored values. The histologic features were
similar for MB, PNET and small cell GBM. Microscopic-
ally, sheets and compact nests of uniform small blue cells
with scant cytoplasm were seen in all lesions, however the
well-formed rosettes were lavish in MB and necrosis was
more common in small cell GBM (Figure 2).
The positive IHC expression of EGFR cases accounted
for 91.18%, 86.67% and 71.43% of MBs, small cell GBMs
and PNETs respectively (Figure 2), and there was noB
ediatrics (≤year 16) CNS small cell tumors. A) The age distribution of
B), 8 cases PNETs and 19 cases small cell glioblastoma (GBM) diagnosed
) The keplan-meier survival curves of MB, small cell GBM and PNET
ll cell GBM: PNET, 0.12. P-values were obtained from two-sided
Table 1 The clinicopathology features and survival time






44 cases (Death) X ± s (months) (<0.05)
Sex 0.346
Male 27(19) 15 ± 5.769
Female 17(12) 24 ± 11.406
Resection stage
Total resection 33(17) 35 ± 4.763 0.0352
Partial resection 11(9) 20 ± 6.020
Therapy <0.0001
Surgery only 27(23) 10 ± 0.975
Surgery + Radiotherapy 17(3) 53 ± 10.29
Ki67 0.051
0,1+, 2+ 21(8) 51 ± 10.29
3+ 13(8) 20 ± 5.503
EGFR (IHC) (34 cases) 0.0001
0,1+, 2+ 20(5) 53 ± 20.82
3+ 14(11) 11 ± 3.338
EGFR (FISH) (34 cases) 0.002
Negative 15(5) 53 ± 19.96
Positive 19(11) 20 ± 7.028
Table 2 The clinicopathology features and survival











Male 13(10) 8 ± 4.676
Female 6(4) 10 ± 0.031
Resection stage 0.0744
Total resection 11(8) 10 ± 1.309
Partial resection 8(6) 4 ± 3.771
Therapy 0.00031
Surgery only 12(10) 3 ± 0.476
Surgery + Radiotherapy 7(4) 11 ± 1.095
Ki67 0.0359
0,1+ 9(6) 10 ± 2.449
2+, 3+ 6(4) 4 ± 0.376
EGFR (IHC) (15 cases) 0.0085
0,1+, 2+ 7(5) 11 ± 1.138
3+ 8(5) 3 ± 1.194
EGFR (FISH) (15 cases) 0.0267
Negative 8(5) 11 ± 1.646
Positive 7(5) 3 ± 1.047
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The negative expression (0) and weakly positive expression
(1+, 2+) cases were consolidated into the low expression
group, compared with strong positive cases (3+). The prog-
nosis of all tumor subgroups with EGFR IHC low expres-
sion (0 ~ 2+) was promising than the one of high
expression groups (3+) by log-rank analysis (Tables 1, 2, 3).
Dual-color FISH analysis was carried out to evaluate for
the gene amplification in the tumor lesions by the number
of signals in each cell related to EGFR and to the centro-
meric region of chromosome 7. Representative positive
images are illustrated in Figure 3A. The average ratio of
EGFR/centromeric region of human chromosome 7
signals was more than 2.0 as calculated positive signals in
each tumor group. The cells with orange clusters were
also determined as positive expression.
The EGFR gene was amplified in 19 out of 34 MB tu-
mors (55.88%), 7 from 15 small cell GBM cases (46.67%)
and 4 cases of 8 PNET samples (50%) assessed by FISH
(Figure 3A). In the vast majority of specimens, the amplifi-
cation was widespread, typically involving nearly all tumor
cells. However, 2 PNET specimens had focal EGFR ampli-
fication, with only 5–10% of tumor cells identified as posi-
tive. The log-rank survival analysis showed that all CNS
small cell tumors patients with EGFR FISH positivesignals had longer median survival time compared with
ones with negative signals (P ≈ 0.002 for MB and GBM)
(Tables 1, 2, 3).
We also analyze the relationship between EGFR IHC
and FISH staining in 3 subgroups and found that the
patients with both protein high expression and gene amp-
lification suffered from the worst prognosis compared
with ones with double negative signals (Table 4). The
overall concordances between EGFR gene amplification
status by FISH and EGFR IHC were 61.76% of MB, 75% of
PNET and 80% of small cell GBM. Notably, EGFR IHC
negative samples should also apply the FISH examination
to help analyze the patient prognosis, for the reason that
the patients who was detected with negative EGFR pro-
tein expression but gene amplification also suffered from
poor prognosis.
The ERBB-2, 3 and 4 gene amplification and protein
expression in CNS small cell tumors
Although previous research suggested that ERBB-2 was
considered as the prognosis factors for the MB [3]. We
did not observe the clear IHC positive signals of ERBB-2
in MB, small cell GBM and PNET samples (Figure 2
ERBB-2). To determine the ERBB-2 gene amplification,
Table 3 The clinicopathology features and survival
distribution of PNET patients
PNET Number of patients Median survival times
8 cases (Cases were dead) X ± s (months)
Sex
Male 4(3) 9 ± 4
Female 4(2) 10
Resection stage
Total resection 4(1) 54
Partial resection 4(4) 10 ± 1.414
Therapy
Surgery only 4(4) 4 ± 3




EGFR (IHC) (8 cases)
0,1+, 2+ 4(1)
3+ 4(4) 4 ± 0.816
EGFR (FISH) (8 cases)
Negative 4(1)








Figure 2 The immunohistochemistry staining of ERBB-2, EGFR and ki-
MB, PNET and small cell GBM respectively; D ~ F) The EGFR expression in M
The ki-67 expression in MB, PNET and small cell GBM respectively (The stain
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GBMs and 4 cases PNETs samples. The results overlapped
with protein expression, no positive signals observed
(Figure 3B). The ERBB-3 and 4 IHC expression was also
negative in all CNS small cell tumor samples (Data not
shown because of the similar features with ERBB-2).
The children CNS small cell tumors treatment options and
their impact on prognosis
Patients with small cell GBM faced a poor prognosis
regardless of surgical procedures, while MB patients with
partial resection suffered worse prognosis compared ones
with total resection (P < 0.0352) (Tables 1 and 2). Al-
though the statistic between two surgical resections was
not calculated because of restriction of patient number for
PNET, the survival time of patients with total resection
was more than 45 months at from time of onset to the
follow-up endpoint (Table 3). The total resection had the
positive impact for the prognosis of MB and PNET
patients.
The study did not involve the radiation exposure time
and dosage, and the result was only the survival function
of postoperative radiotherapy for the prognosis. The total
28 CNS small cell tumors patients (39.44%) were received
postoperative radiotherapy,among which 38.64% (17/44)
MB patients, 50% (4/8) PNET patients and 36.84% (7/19)
small cell GBM respectively. Statistical analysis showed





67 in MB, PNET and small cell GBM. A ~ C) The ERBB-2 expression in
B, PNET and small cell GBM respectively (The staining index: 3+); G ~ I)









Figure 3 The Fluorescence in situ hybridization of EGFR and ERBB-2 in MB, PNET and small cell GBM. A) The positive signals of EGFR gene
amplification in MB (a), PNET (b) and small cell GBM (c); B) The signals of EGFR gene in MB (d), PNET (e) and small cell GBM (f). The bar: 25 μm.
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(Tables 1, 2, 3). The median survival time of MB, PNETs
and small cell GBMs underwent radiotherapy was longer
compared with the pediatric patients only received surgi-
cal resections. To be noticed, the majority of those
received radiotherapy patients were from the urban popu-
lation, while patients without undergoing radiotherapy
and suffered from larger tumor volumes during surgeries
were mainly from economically underdeveloped rural
areas (Data not shown).
The multiple Cox regression analysis of pediatrics CNS
small cell tumors
The multiple Cox regression analysis with overall survival
as the dependent variable was performed for CNS small
cell tumor clinical features with expression of EGFR pro-
tein expression and gene amplification (Tables 5, 6, 7).
After adjusting for age, gender, tumor size, tumor inva-
sion, ki-67, extent of surgical resection and treatment, the
Cox analysis revealed that without-radiotherapy, EGFR
protein overexpression (IHC) and EGFR gene amplifica-
tion (FISH) were the statistically significant poor prognos-
tic factors in patients with MB (P = 0.000013). The other
clinical features, tumor invasion and ki-67 reached no sig-
nificance. The small cell GBM and PNET shared the same
poor prognosis factors which were without-radiotherapy
and EGFR protein overexpression. The limited number of
tumor cases may be the reason for the EGFR amplification
was not involved in the Cox regression of small cell GBM
and PNET.Discussion
In this research, we concentrated on the prognostic fac-
tors for the pediatrics CNS small cell tumors contained
small cell GBM, PNET and MB. In the Background part,
we already indicated the reason why we grouped them to-
gether for the similar genetics or histopathology charac-
ters. EGFR protein overexpression was determined as the
negative prognostic factor for all small cell CNS tumors in
our research. EGFR gene amplification was evaluated ne-
cessarily by means of FISH in MB. Even for the small cell
GBM and PNET, the disease-free survival time of negative
FISH signals was longer than the one of positive signals.
We assumed that the limited number of cases was the rea-
son for that the Cox analyses excluded the EGFR amplifi-
cation from the prognostic factors of small cell GBM and
PNET.
The relationship has been correlated the presence of
small cell architecture in primary GBM with EGFR amp-
lification [18]. Combination of an anti-EGFR agent Iressa
and a JAK2/STAT3 inhibitor synergistically suppressed
STAT3 activation and potently killed GBM cell lines that
expressed EGFR [19]. However, Alterations of CDKN2A,
EGFR, CDK4, and MDM2 genes, commonly implicated
in gliomagenesis, were not identified in any PNET,
which was opposite with our results [20]. Aberrant acti-
vation of Hedgehog (HH) signaling has been identified
as a key etiologic factor in MB [21]. Frank Götschel
et al. identified a novel crosstalk mechanism whereby
EGFR signaling silences proteins acting as negative regu-
lators of HH signaling [22]. The effects of the EGFR
Table 4 The FISH and IHC detection of EGFR signals in
CNS small cell tumors




MB (34) + -
+ 10 (10.75 ± 4.1) 4 (29.51 ± 2.33)
- 9 (21.14 ± 3.29) 11 (59.18 ± 10.21)
FISH
GBM (15) + -
+ 6 (2.5 ± 1.1) 2 (4)
- 1 (10) 6 (12.27 ± 2.21)
FISH
PNET (8) + -
+ 3 (3.5 ± 2.1) 1 (11)
- 1 (5) 3 (all alive > 54)
Note: FISH: Fluorescence of in situ hybridization; IHC: immunohistochemistry.
Table 6 The multiple cox regression analyses of
small cell GBM
The prognosis related factors RR P
Radio-therapy 9.85 0.0017
EGFR (IHC) 8.34 0.00389
No-related factors Score P
Age 0.00762 0.93
Tumor size 0.002 0.97
Resection extent 0.009 0.92
Ki-67 1.302 0.25
EGFR (FISH) 1.526 0.22
Vascular proliferation 2.162 0.14
Liu et al. Diagnostic Pathology 2014, 9:132 Page 8 of 10
http://www.diagnosticpathology.org/content/9/1/132inhibitor gefitinib on cell growth and signaling were
evaluated in three MB cell lines (D283, D341, Daoy),
and gefitinib induced G0/G1 arrest in all lines, indicating
that gefitinib might be a molecularly targeted agent for
the treatment of MB [23]. As those data indicated, the
mechanism of EGFR over-activation in CNS small cell
tumors is still ambiguous. The deepen study combining
clinical bed to bench is required. At the meantime, the
molecular inhibitors of EGFR tyrosine kinases (erlotinib
or gefitinib) should be considered as the effective indi-
vidualized treatment and start the consortium study in
China for pediatrics CNS small cell tumors.
According the previous results, ERBB-2 and ERBB-3
mRNAs were detected only in a few high-grade gliomas,
while ERBB-4 expression was most pronounced in low-
grade gliomas [24]. It was also reported that ERBB-2 and
ERBB-4 are highly expressed in aggressive forms of me-
dulloblastoma [25]. However, ERBB-4 expression was
downregulated in HH signaling-induced MBs from mice.Table 5 The multiple cox regression analyses of MB
The prognosis related factors RR (relative ratio) P
Radio-therapy 27.81616515 0.0000133
EGFR (IHC) 14.31869361 0.000154325
EGFR (FISH) 8.9986669 0.002701766
No-related factors Score P
Age 4.021743642 0.054917253
Gender 0.060643558 0.805481647
Tumor size 1.300125433 0.254190313
Resection extent 2.503056978 0.113625548
Ki-67 3.761288415 0.052452147
Invasion 0.841301195 0.359024894According to the animal experiments, HH signalling
inhibited ErbB-4 expression in mouse cerebellar granule
progenitors and human MB cells [26]. And the other re-
searchers also suggested that expression of ERBB-2 is
much lower on MB tumor cells than on breast cancer
cells, so they are not susceptible to ERBB-2 monoclonal
antibodies, like trastuzumab (Herceptin) [5]. The expres-
sion and amplification of ERBB-2 and ERBB-4 were not
pronounced in MB, PNET and small cell GBM detected
by FISH and IHC according our results. Expanding the
number of cases will offer more evidence for the ERBB-2
and ERBB-4 expression. It is now recognized that MB is a
collection of heterogeneous entities with disparate demo-
graphics, transcriptomes, genetics, and clinical outcomes
[27]. According to international consensus, the principle
subgroups of MB are WNT, SHH, Group 3, and Group 4
[28]. Because our prognostic study did not account for
these subgroups, we hypothesized that the difference of
EGFR family members expression in MB could have
resulted from differential subgroup representation among
studies.
We have found that all children patients involved in this
study did not receive any chemotherapy and only 39.44%
of patients underwent the radiotherapy after surgery.Table 7 The multiple cox regression analyses of PNET
The prognosis related factors RR P
Radio-therapy 6.624 0.01
EGFR (IHC) 5.66 0.022
No-related factors Score P
EGFR (FISH) 4.82 0.038
Age 0.697057605 0.403774151
Gender 0.999869375 0.317342117
Tumor size 2.789838274 0.094863801
Resection extent 2.190441949 0.138869465
Ki-67 3.55940479 0.059208966
Invasion 1.772277228 0.183100505
Liu et al. Diagnostic Pathology 2014, 9:132 Page 9 of 10
http://www.diagnosticpathology.org/content/9/1/132Other researchers have reported a median survival of
14.3 months for small cell GBM [29]. With present means
of surgery, craniospinal radiotherapy, and chemotherapy,
between 75% and 90% of children greater than 3 years of
age with nondisseminated MB are likely to be survivors
5 years after treatment [4]. Compared with those promis-
ing prolonged survival time in western countries, the
median time of MB and small cell GBM in our hospital
was only 2 years and 8 months. We assumed that the
short disease-free survival time was affected by the less of
radiotherapy. Infants and children with supratentorial
PNET and MB are special compared with adult patients
for long-term neurocognitive development being consid-
ered. This is not only due to the whole-brain radiation
therapy these children are often treated with, but also
due to the local effects of the tumor and the need for
higher-dose boost radiotherapy. In the future, the children
cognitive levels should be involved when considering the
treatment and prognosis, which will lead more challenge
for neurosurgeons and social work.
Conclusion
Overexpression of EGFR predicts poor outcomes of MBs,
small cell GBMs and PNETs, suggesting those three sub-
types can be considered as one group for the potential
common mechanism. The current individual treatment
and big data analysis of pediatric CNS embryonal tumors
and GBM continues to be very challenging in China. Our
data provided information for the planning of pediatric
CNS tumor treatment and control programs, especially
for prognosis prediction and the necessary of post-surgery
radiotherapy. The more detailed and large-scale follow-up
analysis is summoned in China.
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